Lexaria Bioscience Corp. Achieves Global Patent Milestone with 50 Patents
Lexaria Bioscience Corp. has reached a significant milestone with 50 patents granted worldwide, including new patents for epilepsy treatment and sublingual nicotine delivery, marking a pivotal moment in the company's strategy to expand its drug delivery platform.
Lexaria Bioscience Corp. has announced the receipt of two new international patents, bringing its total worldwide patent portfolio to 50. This achievement underscores the company's commitment to broadening its intellectual property in the drug delivery sector. The new patents include one in Australia for the treatment of epilepsy and another in Japan for the sublingual delivery of nicotine, both utilizing Lexaria's DehydraTECH™ technology.
The epilepsy treatment patent expands Lexaria's protection outside the USA, where it already holds six patents, with the new patent set to expire in 2044. The nicotine delivery patent in Japan complements existing patents in the USA and Canada, with an expiration date of 2043. These developments are significant given the epilepsy drug market's projected growth to over $15 billion by 2032 and the global retail oral nicotine market's expected annual growth rate of 26% until at least 2030.
Rich Christopher, CEO of Lexaria, highlighted the strategic importance of these patents in enhancing the company's commercial prospects within the pharmaceutical industry and creating long-term value for shareholders. The DehydraTECH™ technology has demonstrated potential in improving drug absorption and delivery, particularly in the nicotine pouch market, which is anticipated to reach $25.4 billion in revenue by 2030.